GLP1R and neurodegenerative disease: We also explored common metabolic mechanisms between neurodegenerative diseases such as DE and AD, and developed therapeutic strategies for metabolic reprogramming such as GLP-1 receptor agonists, NAD+ boosters, and AMPK activators.